Immobilized BTLA Protein, Human, Recombinant (aa 1-134, His) (Cat#TMPY-07085) at 2 μg/ml (100 μl/well) can bind Recombinant Mouse HVEM/TNFRSF14 Protein (His & Fc Tag), the EC50 is 11-33 ng/mL.

BTLA Protein, Human, Recombinant (aa 1-134, His) is expressed in HEK293 Cells. The accession number is Q7Z6A9.

Human

HEK293 Cells

CD272,BTLA1

A DNA sequence encoding the Human BTLA (NP_001078826.1) (Met1-Thr134) was expressed with a polyhistidine tag at the C-terminus.

≥ 95% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC.

Please refer to the lot-specific COA.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

BTLA is a inhibitory molecule which belongs to the Ig superfamily. It down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is crucial to understand the mechanism(s) of action of these antibodies before attempting clinical applications. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy